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Evaluating the number, phenotypic characteristics, and function of immunosuppressive cells in the tumor microenvironment
and peripheral blood could elucidate the antitumor immune response and provide information to evaluate the eﬃcacy of cancer
vaccines.Furtherstudiesareneededtoevaluatethecorrelationbetweenchangesinimmunosuppressivecellsandclinicaloutcomes
of patients in cancer vaccine clinical trials. This paper focuses on the role of T-regulatory cells, myeloid-derived suppressor cells,
and tumor-associated macrophages in cancer and cancer immunotherapy and their role in immune monitoring.
1.Introduction
In April 2010, the U.S. Food and Drug Administration
(FDA) approved sipuleucel-T (Provenge, Dendreon Corp.,
Seattle,WA)forthetreatmentofasymptomaticorminimally
symptomatic metastatic castration-resistant prostate cancer
(mCRPC). Provenge has been shown to improve overall
survival in mCRPC patients by 4.1 months compared to
placebo (25.8 months versus 21.7 months, resp.; P = .032;
HR: 0.775; 95% CI: 0.614, 0.979) [1]. Approval of the
ﬁrst therapeutic cancer vaccine is a milestone in cancer
immunotherapy; nevertheless, the question still remains:
how do therapeutic cancer vaccines work? Immune response
to a pathogen (i.e., virus, bacterium, yeast) or to tumor
cellsisacomplex,incompletelyunderstoodprocessinvolving
multiple factors.
Therationalefortherapeuticcancervaccines(asopposed
to preventive cancer vaccines, which are not the subject
of this paper) arose from the hypothesis that the cancer
cells are under surveillance of a healthy immune system,
and that cancer spreads when the host immune system fails
to control the growth of tumor cells. The speciﬁc reasons
for this failure of the immune system are not well known.
In the last decades, much research in cancer immunology
has focused on deﬁning tumor-speciﬁc antigens or tumor-
associated antigens (TAAs) capable of inducing an immune
response against tumors. Various vaccine strategies and
modalities have also been tested in an eﬀort to achieve this
goal [2, 3]. To date, this pursuit has encountered some
major obstacles. The lack of a strong antitumor response
might be related to the intrinsic nature of the tumor
antigen itself which, unlike a viral or bacterial invader, is
usually a self-antigen. Moreover, a weak immune response
is frequently associated to the treatment (i.e., chemotherapy
or radiotherapy) the cancer patient has previously received.
This should thus be taken into account when designing
clinical trials employing a combination of cancer vaccines
and standard therapies. Particular emphasis should also be
placed on the optimal schedule for the various treatments
because, while chemotherapy and radiotherapy can have
an immunosuppressive eﬀect, studies have shown that they
may also increase the expression of several TAAs on tumor
cells, or cause a “rebound eﬀect” on immune cells that can
be used to enhance the antitumor response (see [3]f o r
review). In this scenario, the analysis of the immunological
eﬀects of targeted therapies that use antibodies and small2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of the potential role of the immune suppressive cells (ISCs) in cancer. The release into the circulation of
ISCs derived from thymus (nTregs) or from bone marrow (MDSCs) is partially driven by factors secreted by the tumor. Successively, ISCs
can migrate into the tumor site (or a draining lymph node). Moreover, several factors produced in the tumor microenvironment may induce
the conversion of CD4+ T cells into iTregs or drive the polarization of monocytes towards a M2-phenotype. All these phenomena lead to
an inhibition of CD4+ T-helper cells and cytotoxic T lymphocytes (eﬀector cells), resulting in a general decrease of the antitumor immune
response. Theoretically, the release of ISCs from the thymus, the bone marrow, and the tumor site to the peripheral blood could reﬂect the
immunosuppressive status of the antitumor immune response and could be of use in the real time immune monitoring of patients enrolled
in therapeutic vaccine clinical trials. HPC: hematopoietic progenitor cells; CMP: committed myeloid progenitors; nTreg: thymic-derived,
naturally occurring regulatory T cells; iTreg: induced or adaptive regulatory T cells; MDSC: myeloid-derived suppressor cells; TAM-M2:
tumor-associated macrophages characterized by M2-polarization; CTL: cytotoxic T lymphocytes.
moleculestoinhibitspeciﬁcmolecularpathwaysisalsobeing
evaluated.
Althoughpreclinicaldatahaveshownthatitispossibleto
break tolerance to a speciﬁc self-antigen, most clinical trials
employing cancer vaccines have mostly failed to demonstrate
a real advantage in terms of long-lasting clinical responses or
prolonged overall survival. In an immunocompetent cancer
patient, the immune system actually suppresses attacks
against self-antigens, including TAAs, particularly in the
tumor microenvironment. Recently, research has focused
moreonthesuppressivecomponentoftheimmuneresponse
in “breaking tolerance” and in steering the immune system
toward “autoimmunity.”
The major components of the suppressive compartment
of the immune system are a group of heterogeneous immune
cells. One of the major problems in characterizing these
cells is their extreme plasticity. Cells normally committed
to activating an immune response can transiently acquire
suppressive characteristics. This is no doubt an impor-
tant mechanism by which the immune system ﬁne-tunes
a speciﬁc immune response, balancing the number and
function of immune cells involved in the process. Moreover,
the heterogeneity and plasticity of this compartment of
the immune system makes it diﬃcult to deﬁne by cellular
markers. A schematic representation of the specialized
immune suppressive cells involved in the antitumor immune
response is shown in Figure 1. A better understanding of
the mechanisms that regulate the homeostasis of these
suppressive cells could lead to development of more eﬀective
cancer immunotherapies and better immune monitoring of
patients receiving cancer vaccines, and ultimately help to
answer the question: how do cancer vaccines work? This
paper will focus on the role of T-regulatory cells, myeloid-
derived suppressor cells, and tumor-associated macrophages
in cancer immunotherapy and immune monitoring.
2.Regulatory TCells
Regulatory T cells (Tregs) are a specialized subpopulation
of T cells characterized by their ability to directly or
indirectly suppress T-cell activation. Since their discovery
in the early 1970s [4–6], the deﬁnition of Tregs has
continually changed due to their extreme heterogeneity
and lack of speciﬁc markers. In mice, Tregs are universally
characterized by concurrent expression of CD4, CD25, and
FoxP3. Although FoxP3 expression is an essential identiﬁerJournal of Biomedicine and Biotechnology 3
of this population in humans, it is not suﬃcient, since
most activated CD4+ T cells can transiently express FoxP3.
For this reason, several diﬀerent markers have been pro-
posed to further deﬁne the phenotype of Tregs, including
CD127, cytotoxic T-lymphocyte antigen 4 (CTLA-4), HLA-
DR, glucocorticoid-induced TNFR-related protein (GITR),
lymphocyte-activationgene3(LAG-3),CD45RA,andCD39.
Unfortunately, since none of these has been demonstrated
to be Treg speciﬁc [7], there is still a lack of clearly deﬁned
markers for human Tregs.
To date, there are at least 2 recognized populations
of Tregs characterized by the expression of FoxP3: (1)
thymic-derived, naturally occurring Tregs (nTregs) that
constitutively express FoxP3, and (2) induced or adaptive
Tregs (iTregs), such as CD4+CD25− T cells that peripherally
acquire the immunosuppressive characteristics of Tregs.
Recently, it was demonstrated that these 2 lineages can
be distinguished by analysis of demethylation within the
FoxP3 locus [8]. To further complicate matters, at least
2 other populations of CD4+ T cells are characterized by
immunosuppressive activities: Tr1 and Th3. Unlike Tregs
that require cell-to-cell contact to exert their suppressive
activity, Tr1 and Th3 cells suppress mainly by the release of
IL-10 and TGF-β,r e s p e c t i v e l y .
The role of CTLA-4 expression on human Tregs has
been investigated for several years. CTLA-4 is expressed
both within and on the surface of CD4+ T cells and Tregs,
and is a negative regulator of T-cell activation. CTLA-4
counteracts the function of the costimulatory protein CD28
during antigen presentation. In fact, both molecules bind
to CD80 and CD86 on antigen-presenting cells (APCs),
but while CD28 transmits a stimulatory signal to T cells,
CTLA-4 transmits an inhibitory signal, resulting in impaired
T-cell activation. Expression of CTLA-4 on the surface of
CD4+ T cells is induced in response to TCR ligation, and
evidently represents a mechanism of autoregulation of the
immune response. In contrast, CTLA-4 is constitutively
expressed on the surface of Tregs, suggesting a possible
core contribution of CTLA-4 in Treg-mediated suppression
[9]. Recent ﬁndings have shown that Treg-speciﬁc CTLA-4
deﬁciency in conditional knockout mice is associated with
a profound reduction in immune suppressive capacity [10].
In addition, blockade of CTLA-4 by speciﬁc antibodies has
been shown to enhance immune responses against cancer
in several clinical trials [11–14]. It is unclear, however,
whether the primary target of these blocking antibodies is
the eﬀector T cells or the regulatory T-cell compartment.
Studies in mice have shown that anti-CTLA4 monoclonal
antibody (MAb) can enhance the avidity of eﬀector T cells
[15, 16]. Findings in mice expressing a chimeric CTLA-4
composed of the human extracellular domain have shown
thataconcomitantblockadeofbothcompartmentsleadstoa
synergistic eﬀectand maximal antitumor activity [17]. These
data indirectly indicate the importance of balance between
the stimulatory and inhibitory compartments generated
during an antitumor immune response. A better under-
standing of these mechanisms could aid the development
of novel immunotherapeutic strategies in the treatment of
cancer.
3. Tregs in Cancer Immunotherapy and
Immune Monitoring
Increased numbers and/or enhanced functionality of Tregs
havebeendetectedintheperipheralbloodmononuclearcells
(PBMCs), the tumor microenvironment, and in draining
lymph nodes of patients with hematologic malignancies
[18–20] and various types of solid tumors [21–33]. Several
studies have demonstrated that Treg depletion can be used
eﬃcientlytoenhancevaccine-mediatedantitumorimmunity
in cancer patients [34–36]. A direct correlation has also been
demonstrated between the frequency and function of Tregs
and overall survival [35, 37–39].
Arandomizedplacebo-controlled43-centerPhaseIItrial
in patients (n = 125) with mCRPC employing a poxviral-
based vaccine containing the transgenes for PSA and 3
costimulatory molecules (PSA-TRICOM) demonstrated a
statistically signiﬁcant (P = .0061) survival advantage in
the vaccine arm. In a recent study at the National Cancer
Institute (NCI) employing the same vaccine, we investigated
the number, phenotype, and functionality of Tregs in 32
patients with mCRPC. The median overall survival for these
patients was similar to that observed in the multicenter trial
of 26.6 months, with a median followup of 44.6 months;
this was an improvement of 9.2 months over the median
predicted survival of 17.4 months in a comparable patient
population, as calculated by the Halabi nomogram [40].
Interestingly, the subpopulation of patients with a Halabi-
predicted survival (HPS) >18 months (i.e., patients with low
tumor burden) seemed to beneﬁt most from PSA-TRICOM
vaccination, with an actual overall survival of ≥37.3 months
(median not reached) compared to an HPS of 20.9 months
(P = .035) [41]. In evaluation of PBMC of these patients, we
found a signiﬁcant correlation between overall survival and
Tregsuppressivefunctionafter3monthlyvaccinationsversus
prevaccination (P = .029). Of patients with overall survival
> HPS, 80% had decreased Treg function after 3 monthly
vaccinations.Ontheotherhand,75%ofpatientswithoverall
survival < HPS showed increased Treg suppressive activity.
We also investigated whether these changes in terms of Treg
functionality could be related to phenotypic modiﬁcations
on the surface of these cells. Based on previously published
research [9], we looked at the expression of CTLA-4 as a
potential marker of Treg-mediated suppression and found
a signiﬁcant correlation between the ratio of CD4+CD25−
(eﬀector) cells to CTLA-4+ T r e g sa n dt h eo v e r a l ls u r v i v a lo f
thesepatients.Inparticular,wefoundthattheratioincreased
after 3 monthly vaccinations in the subgroup of patients
with overall survival > HPS (P = .029) and decreased after
vaccination in the subgroup with overall survival < HPS
(P = .027) [42].
Altogether, these data suggest an association between
changes in Treg function after vaccination and clinical out-
comes, leading to either or both of the following hypotheses:
(a)thesechangesareadirectconsequenceofthepostvaccina-
tion immune response, and/or (b) they reﬂect tumor burden
and tumor escape mechanisms. Further studies are needed
to address these questions. Potentially, Treg function and/or
phenotype and the ratio of eﬀector:CTLA-4+ Tregs could4 Journal of Biomedicine and Biotechnology
potentially be used to monitor immune function (the bal-
ance between immunostimulatory and immunosuppressive
factors) in patients enrolled in clinical trials of therapeutic
cancer vaccines. Analysis of Tregs in real time as part of the
immunemonitoringofpatientscouldalsohelpinidentifying
the subpopulation of patients who would most likely beneﬁt
from vaccine therapy versus those who would not.
4.Myeloid-DerivedSuppressorCells
Myeloid-derived suppressor cells (MDSCs) are a heteroge-
neous cell population composed mainly of myeloid progen-
itor cells that do not completely diﬀerentiate into mature
macrophages, dendritic cells, or granulocytes. Immature
bone-marrow-derived myeloid cells (IMCs) represent less
than 1% of PBMCs in healthy individuals; characteristically,
they retain the ability to terminally mature. In various
diseases,includingcancer,thissubsetofcellscanbeincreased
4- to 10-fold, which is associated with partially blocked
diﬀerentiation and acquisition of suppressive activity [43].
Thus, MDSCs represent critical regulators of antitumor
immunity, since they can potentially inhibit both tumor-
speciﬁc and nonspeciﬁc T-cell responses. MDSCs have
also been shown to regulate immune responses during
bacterial and parasitic infections and inﬂammation as well as
autoimmunity [44–47]. Interestingly, a transient expansion
of MDSCs has been observed after immunization with
various antigens, as well as recombinant vaccinia virus
expressing IL-2 [48–50].
Mouse MDSCs characteristically express markers of
myeloid lineage, such as myeloid diﬀerentiation antigen
(Gr1)andintegrinalphaM(CD11b,alsocalledmacrophage-
1 [Mac-1] antigen), but they typically lack myeloid cell
maturation markers. In humans, the absence of a Gr1
gene homolog has made the deﬁnition of MDSCs more
challenging, and has led to the use of combinations of
several diﬀerent phenotypic markers, such as CD11b, CD34,
CD33, CD15, CD13, CD14, IL-4Rα, and HLA-DR [48].
MDSCs can be roughly divided into 2 major subpopulations:
granulocytic (PMN-MDSCs)and monocytic (MO-MDSCs).
While both of these subpopulations are characterized in
humans by expression of CD33, CD11b, and IL-4Rα, they
diﬀer in terms of CD14 and CD15 levels (CD14−CD15+ for
PMN-MDSCs; CD14+CD15− for MO-MDSCs).
Because of the vast heterogeneity of MDSCs, several
diﬀerent mechanisms of suppression have been proposed
for various subpopulations of these cells [49]. A major
fraction of MDSCs express high levels of intracellular
arginase, an enzyme responsible for the catabolism of L-
arginine, a nonessential amino acid required by many
cells, including T cells, for protein synthesis. Uptake of
L-arginine by MDSCs can rapidly lead to depletion of
this amino acid, resulting in a T-cell arrest in the G0-G1
phase [50]. Moreover, PMN-MDSCs can also suppress T
cells by producing reactive species of oxygen, while the
suppressive function of MO-MDSCs is generally mediated
by inducible nitric oxide synthase (iNOS). A third potential
mechanism of suppression may be related to the ability
of CD14+HLA-DR−/lo to induce Tregs and inhibit natural
killer cells [51, 52]. Other mechanisms have also been
proposed, such as sequestration of cystine (the main form
of cysteine in the oxidizing extracellular environment) by
MDSCs. In fact, the only form of cysteine available to T
cells comes mainly from APCs during antigen processing
and presentation, since lymphocytes lack both the enzyme
(cystathionase) responsible for synthesis of this amino acid
and the xCT chain of the xc
− cystine transporter. MDSCs
have been shown to express high levels of the xCT chain
needed to import cystine, but they lack the alanine-serine-
cysteine transporters needed to export cysteine. This results
in sequestration of cystine from the extracellular space that
ultimately leads to lower levels of cysteine available for T-cell
activation.MDSCscouldalsoactindirectlybyinducingTregs
in the tumor microenvironment in the presence of IL-10 and
IFN-γ, or promoting Treg expansion by acting as tolerogenic
APCs [53, 54]. Finally, MDSCs could impair the homing
of na¨ ıve T cells to draining lymph nodes by shedding L-
selectin (CD62-L), operated by the ADAM metallopeptidase
domain 17 (ADAM17, also called TACE, for tumor necrosis
factor-α-convertingenzyme),atransmembraneglycoprotein
highly and constitutively expressed on the surface of MDSCs
[49, 55]. Since ADAM17/TACE has also been related to the
shedding of other important proteins involved in tumor
growth and tumor escape mechanisms, such as mucin 1
and the major histocompatibility complex class I chain-
related gene-A (MICA), the constitutive expression of this
“sheddase” on the surface of MDSCs may cast new light on
the basic mechanisms of cancer progression, in which the
accumulation of MDSCs in the tumor site could play an
important role.
5. MDSCs in Cancer Immunotherapy and
Immune Monitoring
The characteristic heterogeneity of MDSCs probably reﬂects
the plasticity of this cell population in response to diﬀerent
signals received from the tumor microenvironment. In fact,
each particular tumor microenvironment seems to have a
unique eﬀect on the composition of cancer-induced MDSCs,
throughthereleaseofvarioustumor-derivedfactorsinvolved
in the expansion and activation of MDSCs. Cyclooxy-
genase 2, prostaglandins, granulocyte-macrophage colony-
stimulating factor (GM-CSF), macrophage CSF (M-CSF),
IL-6, IL-10, vascular endothelial growth factor (VEGF),
stem-cell factor, IL-3, FMS-related tyrosine kinase 3 (FLT3),
and cell-expressed molecules (such as Notch) have been
implicated in the expansion of MDSCs. Most of these
factors trigger signaling pathways involving Janus kinase
(JAK) protein family members and signal transducer and
activator of transcription 3 (STAT3). IFN-γ, ligands for Toll-
like receptors, IL-4, IL-13, and TGF-β seem to be involved
in the activation of MDSCs by STAT6, STAT1, and nuclear
factor-κB[ 56].
Recently,asubpopulationofMO-MDSCsphenotypically
deﬁned as CD14+HLA-DR−/lo was shown to be signiﬁcantly
expanded in patients with metastatic melanoma, hepatocel-
lular carcinoma, glioblastoma, and prostate cancer [51, 57–
59]; increased circulating MDSCs have been correlated withJournal of Biomedicine and Biotechnology 5
tumor stage and metastatic spread in diﬀerent types of
tumors [54, 60]. Moreover, it has been demonstrated that
MDSCs can be diﬀerently aﬀected by some standard of care
therapies such as sunitinib, doxorubicin-cyclophosphamide,
and docetaxel and by some immunotherapies [57, 60–62].
These ﬁndings suggest a potential use for these cells in
immune monitoring of cancer patients.
We have recently investigated the frequency of
CD14+HLA-DR−/lo or CD11b+CD33+ cells in the PBMCs of
patientswithmCRPCbeforeandaftervaccinationwithPSA-
TRICOM. Our preliminary results show that the percentage
of these populations of MDSCs was signiﬁcantly higher
than in age-matched healthy controls. Moreover, 7 out of
10 patients with overall survival > HPS showed a decreased
frequency of MDSCs after vaccination. Further studies
involving a range of human malignancies are obviously
warranted to validate and/or expand these ﬁndings.
6. Tumor-AssociatedMacrophages
Up to 50% of a malignant tumor mass can be composed
of M2-polarized tumor-associated macrophages (TAMs).
Similar to Th1/Th2 polarization, monocytes in circulating
blood can peripherally acquire diﬀerent characteristics in
response to environmental changes, assuming distinctive M1
(classical activation) or M2 (alternative activation) features.
Exposure to microbial products, such as lipopolysaccharides,
or IFN-γ determines the acquisition of M1 polarization
and cytotoxic functions. M1-macrophages have the ability
to present antigens and activate T cells. They produce high
levels of IL-12, IL-23, and toxic intermediates such as nitric
oxide and reactive oxygen intermediates. Altogether, this
activation leads to a proinﬂammatory response aimed at
killing microorganisms and tumor cells. On the other hand,
the presence of Th2-related cytokines (such as IL-4, IL-10,
and IL-13) or glucocorticoids can drive the diﬀerentiation of
peripheral monocytes toward an M2 phenotype, character-
ized by production of low levels of inﬂammatory cytokines
and high amounts of TGF-β. M2-macrophages mainly func-
tionasscavengers,expressingsurfacemarkerssuchasCD206
(mannose receptor) and CD204 (scavenger receptor A) and
can promote angiogenesis (they are physiologically involved
in repairing and remodeling wounded/damaged tissues).
It has been shown that TAMs are primarily characterized
by M2-polarization and are capable of promoting tumor
growth, neoangiogenesis, invasion, and metastasis by several
mechanisms [63, 64].
7. TAMs in Cancer Immunotherapy and
ImmuneMonitoring
Clinical studies have demonstrated a correlation between
increased numbers of TAMs and poor prognosis for eso-
phageal, bladder, prostate, endometrial, breast, and lung
cancers [65–70]. In addition, TAMs have recently been
associated with expression of VEGF and epidermal growth
factor receptor in breast tumor cells [71], and have been
shown to correlate with vessel density in several malig-
nancies [72–74]. The aminobisphosphonate zoledronic acid,
routinely used to prevent skeletal-related events in patients
with bone metastases, has recently been shown to delay
disease progression and improve survival in patients with
diﬀerent types of advanced cancers [75, 76]. One of the
mechanisms by which bisphosphonates prevent disease
progression could be related to the inhibition of myeloid
diﬀerentiation, leading to a decrease in TAMs and a shift
from M2- to M1-macrophages [77].
A speculative analysis of these data could suggest a
possible use of TAMs in the immune monitoring of cancer
patients enrolled in clinical trials employing therapeutic
vaccines. Theoretically, an eﬃcient cancer vaccine should
be able to shift an immune response against tumor toward
a Th1/M1 polarization. This phenomenon could alter the
frequency of TAMs in the tumor microenvironment and,
consequently, in the peripheral blood of cancer patients.
Thus, like Tregs and MDSCs, TAMs could likely be another
suppressive cell population useful for monitoring patients in
the early stage of cancer vaccine therapy.
8. Conclusions
Ourunderstandingofthemechanismsthatregulatesuppres-
sion of immune responses has rapidly increased in recent
years. In particular, the immunosuppressive role played
by speciﬁc immune cells has raised questions about the
importance of the balance between immunostimulation and
immunosuppression in cancer immunotherapy. In many
phase II/III clinical trials, boosting an antitumor immune
response without counteracting the resulting immunosup-
pression has been shown to be only partially eﬀective
in achieving objective responses and/or prolonged overall
survival [78]. Accumulating evidence suggests the potential
of vaccine therapy in combination with treatments specif-
ically aimed at depressing the number and function of
immunosuppressive cells. A recent phase III trial employing
ipilimumab, a monoclonal antibody that targets CTLA-4,
showed an improvement in overall survival of 3.7 months
in patients with advanced melanoma [79]. In addition,
the receptor tyrosine kinase inhibitor sunitinib has been
demonstrated to enhance antitumor immunity by reversing
MDSC-mediated tumor-induced immunosuppression, and
consequently improving type 1 T-cell function in renal cell
carcinoma patients [61].
Evaluation of the balance between the immunostimula-
tory and immunosuppressive compartments of the immune
system could result in an earlier and better understanding
of how a speciﬁc vaccine is working (or not) in a partic-
ular patient. The current assays used to monitor immune
responses in cancer immunotherapy trials (such as enzyme-
linked immunospot assays, tetramer-based assays, intracel-
lular cytokine ﬂow cytometry, antibody tests, proliferation
assays, and reverse transcription polymerase chain reaction)
have shown only some usefulness as surrogate markers for
clinical eﬃcacy [80]. An assay or assays that measure the
balance between immunosuppression and immunostimula-
tion before versus after vaccination may thus ﬁll a pressing
need.6 Journal of Biomedicine and Biotechnology
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